The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
- 15 July 2014
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 190 (2), 145-154
- https://doi.org/10.1164/rccm.201312-2235oc
Abstract
Rationale: Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-β. Exogenous IFN-β restores antiviral activity. Objectives: To compare the efficacy and safety of inhaled IFN-β with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses. Methods: A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2–5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses. Measurements and Main Results: A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-β; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-β (P = 0.004). Conclusions: Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.gov (NCT 01126177).Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trialCMAJ : Canadian Medical Association Journal, 2005
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005
- Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirusThe Journal of Experimental Medicine, 2005
- Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trialThe Lancet, 2004
- Simple procedures for blinded sample size adjustment that do not affect the type I error rateStatistics in Medicine, 2003
- Randomized, comparative study of interferon β-1a treatment regimens in MSNeurology, 2002
- Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort studyThe Lancet, 2002
- Costs of asthma according to the degree of severityEuropean Respiratory Journal, 1998
- The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis.American Journal of Respiratory and Critical Care Medicine, 1996
- Transmission of the Common Cold to Volunteers Under Controlled ConditionsA.M.A. Archives of Internal Medicine, 1958